Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Mulpleta (lusutrombopag) is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease scheduled to undergo a procedure.
• This summary is based on the review of two systematic review(s)/meta-analysis(es). ^[1-2]
• Primary Efficacy Outcomes: Lusutrombopag demonstrated a higher treatment response rate (RR 6.39; 95% CI 3.69, 11.07; p < 0.0001) and a greater proportion of patients avoiding platelet transfusion and rescue therapy for at least 7 days post-procedure compared to placebo (RR 3.42; 95% CI 1.86, 6.26; p = 0.0001).
• Secondary Effectiveness Outcomes: The risk of any bleeding event was significantly lower with lusutrombopag compared to placebo (RR 0.55; 95% CI 0.32, 0.95; p = 0.03).
• Effectiveness in Specific Populations: The efficacy data primarily pertains to patients with severe thrombocytopenia and chronic liver disease undergoing planned invasive procedures.
• Thrombosis Events: Thrombosis event rates were similar between lusutrombopag and placebo (RR 0.79; 95% CI 0.19, 3.24; p = 0.74).
• The reviewed studies provided no subgroup-specific information beyond the general population of patients with severe thrombocytopenia and chronic liver disease undergoing planned invasive procedures.